Skip to content

PolitiKit

Lobbying by Boehringer Ingelheim Canada Ltd.: its registrations, its lobbyists, the bills it has named and every meeting it has reported with federal office holders since November 2021.

← Lobbying

Corporation

Boehringer Ingelheim Canada Ltd.

Meetings this Parliament
18
With MPs
5
Since Nov 2021
45
Active registrations
1

Most recent reported meeting: Sep 21, 2026.

Registrations in effect

In-house (corporation) In effect since Aug 18, 2026

Filed by Rithesh Mishra, Interim President and CEO

Lobbyists

  • Andrew Ransom · Manager, Patient Access
  • Annie Beauchemin · Head, Market Access
  • Brad Thompson · Manager, External & Healthcare Affairs
  • Eve Blanchet · Regional Manager/ QUE, Patient Access and Health Policy
  • James Thompson · Manager, National Health Policy
  • Mehmood Alibhai · Director of Patient Access & Healthcare Policy

Institutions they may lobby: Agriculture and Agri-Food Canada (AAFC), Finance Canada (FIN), Global Affairs Canada (GAC), Health Canada (HC), House of Commons, Indigenous Services Canada (ISC), Innovation, Science and Economic Development Canada (ISED), Patented Medicine Prices Review Board (PMPRB), Prime Minister's Office (PMO), Privy Council Office (PCO), Senate of Canada, Treasury Board Of Canada Secretariat (TBS)

What they're lobbying on (2)
  • Pharmaceutical pricing policy arising from the jurisdiction of the patented medicine prices review board (PMPRB).
  • Arranging meetings to brief government officials on the business of Boehringer Ingelheim Canada Ltd.

Registration 965031-371995-12. Look it up in the official Registry

Reported meetings

Spreadsheet

Filed by Mark Lewis (27), Andrea Sambati (11), Rithesh Mishra (5), Ruta Stauskas (2).

  • Reported by Rithesh Mishra · In-house (corporation)

    • Lori Idlout · Member of Parliament
    • Benjamin Wiles · Chief of Staff, House of Commons
    Arranging meetings to brief government officials on the business of Boehringer Ingelheim Canada Ltd.

    Official report

  • Reported by Rithesh Mishra · In-house (corporation)

    Arranging meetings to brief government officials on the business of Boehringer Ingelheim Canada Ltd.

    Official report

  • Reported by Rithesh Mishra · In-house (corporation)

    Arranging meetings to brief government officials on the business of Boehringer Ingelheim Canada Ltd.

    Official report

  • Reported by Rithesh Mishra · In-house (corporation)

    • Mackenzy Metcalfe · Policy Advisor, Finance Canada (FIN)
    Arranging meetings to brief government officials on the business of Boehringer Ingelheim Canada Ltd.

    Official report

  • Reported by Rithesh Mishra · In-house (corporation)

    • Mackenzy Metcalfe · Policy Advisor, Finance Canada (FIN)
    Arranging meetings to brief government officials on the business of Boehringer Ingelheim Canada Ltd.

    Official report

  • Reported by Mark Lewis · In-house (corporation)

    • Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
    • Jocelyn Milburn · Director, Policy, Innovation, Science and Economic Development Canada (ISED)
    Arranging meetings to brief government officials on the business of Boehringer Ingelheim Canada Ltd.

    Official report

  • Reported by Mark Lewis · In-house (corporation)

    • Justine Frame · Special Assistant, Policy,, Health Canada (HC)
    • Jibril Hussein · Policy Analyst, Health Canada (HC)
    Arranging meetings to brief government officials on the business of Boehringer Ingelheim Canada Ltd.

    Official report

  • Reported by Mark Lewis · In-house (corporation)

    • Maggie Chi · Member of Parliament
    • Justine Frame · Special Assistant, Policy,, Health Canada (HC)
    • Jibril Hussein · Policy Advisor, Health Canada (HC)
    • nora draper · Parliamentary Secretary Assistant;, Health Canada (HC)
    Arranging meetings to brief government officials on the business of Boehringer Ingelheim Canada Ltd.

    Official report

  • Reported by Mark Lewis · In-house (corporation)

    • Justine Frame · Special Assistant, Policy,, Health Canada (HC)
    Arranging meetings to brief government officials on the business of Boehringer Ingelheim Canada Ltd.

    Official report

  • Reported by Mark Lewis · In-house (corporation)

    • Ritu Banerjee · ADM, Innovation, Science and Economic Development Canada (ISED)
    • Jocelyn Milburn · Director, Policy, Innovation, Science and Economic Development Canada (ISED)
    Arranging meetings to brief government officials on the business of Boehringer Ingelheim Canada Ltd.

    Official report

  • Reported by Mark Lewis · In-house (corporation)

    • Karim Bardeesy · MP
    • Miro Froehlich · Director of Policy, Privy Council Office (PCO)
    • Nasser Haidar · Senior Policy Advisor, Privy Council Office (PCO)
    • Galen Richardson · Senior Advisor, Stakeholder Relations, Privy Council Office (PCO)
    and 14 more
    • Peter M. Boehm · Senator, Senate of Canada
    • Martin Moen · Associate Assistant Deputy, Global Affairs Canada (GAC)
    • Ritu Banerjee · ADM, Innovation, Science and Economic Development Canada (ISED)
    • Annahat Kochhar · Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
    • Hosai Zurmati Halim · Senior Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
    • Elizabeth Wong · Senior Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
    • Chase Knight · Parliamentary Secretary, Innovation, Science and Economic Development Canada (ISED)
    • Lisa Xie · Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
    • victoria morton · Senior Communications Advisor,, House of Commons
    • Greg Orencsak · Deputy Minister, Health Canada (HC)
    • sarah Lawley · Assistant Deputy Minister, Health Canada (HC)
    • Pamela Aung-Thin · Assistant Deputy Minister, Health Canada (HC)
    • Sandenga Yeba · Senior Policy Advisor, Health Canada (HC)
    • Justine Frame · Special Assistant, Policy,, Health Canada (HC)
    Pharmaceutical pricing policy arising from the jurisdiction of the patented medicine prices review board (PMPRB).

    Official report

  • Reported by Mark Lewis · In-house (corporation)

    • Shadad Khallidi · Deputy director of policy, Health Canada (HC)
    Pharmaceutical pricing policy arising from the jurisdiction of the patented medicine prices review board (PMPRB).

    Official report

  • Reported by Mark Lewis · In-house (corporation)

    • Ritu Banerjee · ADM, Innovation, Science and Economic Development Canada (ISED)
    • Rodrigo Arancibia · Executive Director, Innovation, Science and Economic Development Canada (ISED)
    Arranging meetings to brief government officials on the business of Boehringer Ingelheim Canada Ltd.

    Official report

  • Reported by Mark Lewis · In-house (corporation)

    • Manuela Tomic · Senior policy advisor, Innovation, Science and Economic Development Canada (ISED)
    Arranging meetings to brief government officials on the business of Boehringer Ingelheim Canada Ltd.

    Official report

  • Reported by Mark Lewis · In-house (corporation)

    • luke carter · Manager, Health Canada (HC)
    Arranging meetings to brief government officials on the business of Boehringer Ingelheim Canada Ltd.

    Official report

  • Reported by Mark Lewis · In-house (corporation)

    • Mike Poitras · Director, Health Canada (HC)
    Arranging meetings to brief government officials on the business of Boehringer Ingelheim Canada Ltd.

    Official report

  • Reported by Mark Lewis · In-house (corporation)

    • Daniel MacDonald · Director General, Drugs for Rare Diseases, Health Canada (HC)
    • Luke Carter · Executive Director, Health Canada (HC)
    • Russell Vallee · Manager, Health Canada (HC)
    • Mike Poitras · Director, Health Canada (HC)
    and 1 more
    • elisha hurlock · Manager, Health Canada (HC)
    Arranging meetings to brief government officials on the business of Boehringer Ingelheim Canada Ltd.

    Official report

  • Reported by Mark Lewis · In-house (corporation)

    • Max Lee · Senior Communications Advisor, Health Canada (HC)
    Arranging meetings to brief government officials on the business of Boehringer Ingelheim Canada Ltd.

    Official report

  • Reported by Mark Lewis · In-house (corporation)

    • Kim Pate · Senator, Senate of Canada
    Arranging meetings to brief government officials on the business of Boehringer Ingelheim Canada Ltd.

    Official report

  • Reported by Mark Lewis · In-house (corporation)

    Health

    Official report

  • Reported by Mark Lewis · In-house (corporation)

    • william fassett · Office Manager, House of Commons
    • Simon Wood · Legislative Assistant, House of Commons

    Health

    Official report

  • Reported by Mark Lewis · In-house (corporation)

    • Sean Casey · Member of Parliament
    • Robert Kitchen · Member of Parlilament, House of Commons

    Health

    Official report

  • Reported by Mark Lewis · In-house (corporation)

    • Jade Mallette · Director of Parliamentary Affairs, House of Commons

    Health

    Official report

  • Reported by Mark Lewis · In-house (corporation)

    • Daniel MacDonald · Director General, Drugs for Rare Diseases, Health Canada (HC)

    Health

    Official report

  • Reported by Mark Lewis · In-house (corporation)

    • Michelle Boudreau · Associate Assistant Deputy Minister, Health Canada (HC)

    Health

    Official report

From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.